Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OFIRMEV vs ARBLI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.
ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.
Management of mild to moderate pain,Management of moderate to severe pain with adjunctive opioid analgesics,Reduction of fever
Spasticity due to multiple sclerosis,Spinal cord injury,Alcohol use disorder (off-label)
IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.
10 mg orally once daily.
Terminal elimination half-life is 2-3 hours in adults (2.5-3 hours in children). Clinically, dosing every 4-6 hours is needed to maintain therapeutic levels.
Terminal elimination half-life of 26 hours (range 20-32 h), supporting once-daily dosing; prolonged in hepatic impairment.
Acetaminophen is primarily metabolized in the liver via conjugation with glucuronide (50-60%) and sulfate (20-30%). A minor amount is oxidized by cytochrome P450 (CYP2E1, CYP1A2, CYP3A4) to a toxic reactive metabolite (NAPQI), which is normally detoxified by glutathione. At toxic doses, glutathione is depleted, leading to NAPQI accumulation and hepatotoxicity.
Primarily hydrolyzed by esterases to baclofen; baclofen is minimally metabolized (mainly renal clearance of unchanged drug).
Primarily renal (85% as sulfate and glucuronide conjugates, 10% as unchanged drug). Less than 5% fecal/biliary.
Primarily biliary (>70%) and fecal elimination; renal excretion accounts for <5% of unchanged drug.
10-25% bound to albumin at therapeutic concentrations.
>99% bound to albumin and alpha-1-acid glycoprotein.
0.8-1.0 L/kg. Indicates distribution into total body water.
0.7 L/kg, indicating extensive tissue distribution.
100% (intravenous); not applicable for other routes as OFIRMEV is IV only.
Oral: 70% (range 60-80%); IV: 100%.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, extend dosing interval to every 8 hours; maximum daily dose 3000 mg.
e GFR ≥30 m L/min/1.73 m²: no adjustment. e GFR <30 m L/min/1.73 m²: use not recommended.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce total daily dose by 50% (max 2000 mg/day). Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose to 50% of standard and extend interval to every 8 hours; maximum 2000 mg/day.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended.
Weight-based: <10 kg: 7.5 mg/kg/dose every 6 hours; 10-50 kg: 15 mg/kg/dose every 6 hours; >50 kg: 1000 mg every 6 hours or 650 mg every 4 hours. Maximum single dose: 15 mg/kg (up to 1000 mg); maximum daily dose: 75 mg/kg (up to 4000 mg).
Not established for patients <18 years.
No specific dose adjustment; consider reduced renal function. For Cr Cl <30 m L/min, extend interval to every 8 hours. Maximum daily dose: 3000 mg in frail elderly or with comorbidities.
No specific dose adjustment required; monitor renal function.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Abrupt discontinuation may precipitate withdrawal reactions including seizures, hallucinations, and life-threatening hyperthermia (similar to baclofen withdrawal).
Risk of serious hepatotoxicity, especially with doses >4000 mg/day or in patients with underlying liver disease,Risk of severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis) – discontinue at first sign of rash,Risk of hypersensitivity reactions including anaphylaxis,Use caution in patients with severe hepatic impairment, active hepatic disease, or alcoholism,Avoid concurrent use of other acetaminophen-containing products
Risk of withdrawal symptoms with abrupt cessation,May cause sedation and dizziness,Use caution in renal impairment,May exacerbate psychiatric disorders,Avoid with alcohol or CNS depressants
Known hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease (relative contraindication without black box)
Hypersensitivity to baclofen or any component of the formulation
No known food interactions. However, avoid excessive alcohol consumption as it may increase the risk of liver damage.
Avoid alcohol. No specific food interactions reported, but take with or without food consistently to maintain stable drug levels.
Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dose use in third trimester may be associated with preterm birth or low birth weight. Avoid prolonged use above recommended doses.
ARBLI (arbaclofen) is not approved for use in pregnancy. No adequate and well-controlled studies in pregnant women. In animal studies, arbaclofen showed no teratogenic effects at doses up to 4 times the maximum recommended human dose based on body surface area. However, fetal toxicity (reduced fetal weight, delayed ossification) occurred at maternally toxic doses. Based on mechanism (GABAB agonist), potential risk cannot be excluded. First trimester: unknown risk; second/third trimester: possible risk of fetal harm from maternal muscle relaxation; third trimester: risk of neonatal withdrawal (hypotonia, respiratory depression) if used near term.
Acetaminophen is excreted in breast milk in low concentrations (M/P ratio approximately 0.9-1.0). Considered compatible with breastfeeding; peak milk levels occur 1-2 hours after maternal dosing. Use lowest effective dose for shortest duration.
No data on excretion in human milk. Arbaclofen is a small molecule (MW 215.68) and likely excreted into breast milk. M/P ratio unknown. Due to potential for serious adverse reactions (e.g., sedation, respiratory depression) in nursing infants, breastfeeding is not recommended during therapy.
No dose adjustment required during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may lead to lower peak concentrations but standard dosing remains effective. Maximum single dose: 1 g; maximum daily dose: 4 g.
No specific dosing guidelines established for pregnancy due to lack of data. Pregnancy may alter pharmacokinetics (increased volume of distribution, renal clearance) potentially requiring dose adjustments; however, no recommendations can be made because drug is contraindicated in pregnancy.
OFIRMEV (acetaminophen) injection is an IV formulation of acetaminophen used for pain and fever management. It is a prodrug that requires no hepatic conversion, providing rapid onset of action. Monitor for hepatotoxicity; maximum daily dose is 4 grams in adults but lower in patients with hepatic impairment or malnutrition. Do not exceed 1 gram per dose. Hypotension and anaphylaxis have been reported. Not interchangeable with oral acetaminophen due to dose equivalency. Use with caution in patients with alcohol use disorder.
ARBLI (arbaclofen) is a prodrug of baclofen used for spasticity. Titrate slowly to avoid CNS depression. Monitor renal function; dose adjustment required in Cr Cl <60 m L/min. Avoid abrupt discontinuation due to withdrawal symptoms. Use with caution in patients with history of substance abuse due to abuse potential.
OFIRMEV is given intravenously for pain or fever.,Do not take additional acetaminophen-containing medications while receiving OFIRMEV.,Report any signs of allergic reaction (rash, itching, swelling, trouble breathing).,Seek immediate medical attention if you experience severe abdominal pain, yellowing of skin or eyes, or dark urine.,Inform your healthcare provider about all medications you are taking, especially blood thinners.
Take exactly as prescribed; do not increase dose without consulting your doctor.,Do not stop taking abruptly; gradual dose reduction is necessary to prevent withdrawal symptoms (hallucinations, seizures, rapid heart rate).,Avoid driving or operating heavy machinery until you know how ARBLI affects you, as it may cause dizziness or drowsiness.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase sedation risk.,Inform your doctor if you have kidney problems, diabetes, or a history of substance abuse.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OFIRMEV vs ARBLI, answered by our medical review team.
OFIRMEV is a Non-opioid Analgesic that works by OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.. ARBLI is a Cephalosporin Antibiotic that works by ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OFIRMEV and ARBLI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OFIRMEV is: IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.. The standard adult dose of ARBLI is: 10 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OFIRMEV and ARBLI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OFIRMEV is classified as Category C. Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dos. ARBLI is classified as Category C. ARBLI (arbaclofen) is not approved for use in pregnancy. No adequate and well-controlled studies in pregnant women. In animal studies, arbaclofen showed no teratogenic effects at d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.